This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Isocitrate dehydrogenase 1 (IDH1)	<p>Mouse and <i>in vitro</i> studies suggest inhibiting mutant IDH1 could help treat IDH1-mutant gliomas. <i>In vitro</i>, AGI-5198 inhibited mutant IDH1 with an IC₅₀ value of 70 nM without also inhibiting wild-type IDH1 at detectable levels. In a mouse xenograft model for human glioma, AGI-5198 decreased levels of the (R)-enantiomer of 2-hydroxyglutarate (2-HG), an oncometabolite specifically produced by the mutant enzyme, and decreased tumor growth compared with vehicle. Next steps include conducting further preclinical development of mutant-selective IDH1 inhibitors and testing the effects of the inhibitors in other IDH1-mutant solid tumors.</p> <p>Agios Pharmaceuticals Inc. has preclinical programs targeting IDH1 and IDH2 in cancers with mutations in the metabolic enzymes.</p> <p>SciBX 6(14); doi:10.1038/scibx.2013.332 Published online April 11, 2013</p>	Patent applications filed; partnered with Celgene Corp.	<p>Rohle, D. <i>et al. Science</i>; published online April 4, 2013; doi:10.1126/science.1236062 Contact: Katharine E. Yen, Agios Pharmaceuticals Inc., Cambridge, Mass. e-mail: katharine.yen@agios.com Contact: Ingo K. Mellinghoff, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: mellingi@mskcc.org</p>